Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
XORTX Therapeutics Inc
XRTX
Primary Symbol:
V.XRTX
Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance...
its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:XRTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 19, 2022 7:00am
New Press Release - XORTX Announces Submission to European Medicines Agency
Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested CALGARY, Alberta, July 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on...
read article.
(379)
•••
vitalina2233
X
View Profile
View Bullboard History
Comment by
vitalina2233
on Jul 17, 2022 6:45pm
RE:100% up in a day , huge gain just a start
GROW UP F@CK FACE Papi
(259)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jul 15, 2022 9:42am
Back to 1.50 again? I say yes
Told you so
(259)
•••
moneywinner1
X
View Profile
View Bullboard History
Comment by
moneywinner1
on Jul 14, 2022 9:48am
RE:This is going nowhere,
I told you , CEO is not capable to make this a winner
(259)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jul 13, 2022 10:44am
100% up in a day , huge gain just a start
But Ceo should be changed
(259)
•••
moneywinner1
X
View Profile
View Bullboard History
Comment by
moneywinner1
on Jul 13, 2022 10:25am
RE:After good news there is bad one
Just watch
(259)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jul 13, 2022 10:24am
This is going nowhere,
You buy you loose stock
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 13, 2022 7:00am
New Press Release - XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
Clinical Trial Shows Substantially Improved Bioavailiability CALGARY, Alberta, July 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 07, 2022 7:00am
New Press Release - XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)
CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(48)
•••
NLMoose
X
View Profile
View Bullboard History
Post by
NLMoose
on Jun 23, 2022 10:08am
XORTX Now Following IM Cannabis' Evil Path
XORTX Therapuetics was a company with great promise and now they face the same fate as IM Cannabis in becoming IM Delisted.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 21, 2022 7:00am
New Press Release - XORTX Announces "Fireside Chat" with XORTX CEO
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(26)
•••
diamondlessnono
X
View Profile
View Bullboard History
Comment by
diamondlessnono
on Jun 13, 2022 11:11am
RE:RE:After good news there is bad one
Why do u worry when everyone is losing on todays markets. Bitcoin. Gold and on and on and on. SORRY WELCOME TO THE REAL WORLD.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 13, 2022 8:55am
New Press Release - XORTX to Present at BIO International Convention 2022
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(54)
•••
Richmond
X
View Profile
View Bullboard History
Comment by
Richmond
on Jun 11, 2022 2:11am
RE:After good news there is bad one
You are dead on!!! These mf's are fooling the investors
(54)
•••
Richmond
X
View Profile
View Bullboard History
Post by
Richmond
on Jun 11, 2022 2:09am
Depressing Share Price
How many more investors can afford to lose, like the ones that saw XORTEX rolled back at $10.00 and now down to $1.00. Really sickening!! Stockhouse Logo Search Companies, etc News Press Releases
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This Small-Cap Gold Stock Jumped Almost 50% on Friday
Nanalysis Scientific Corp. Announces First Quarter 2024 Results